spacer
home > ict > autumn 2016 > get involved
PUBLICATIONS
International Clinical Trials

Get Involved

Several studies have shown that applications of mHealth in healthcare settings have improved medication and procedural compliance (1); however, little research has been conducted on the effect of mHealth on clinical trial adherence and patient retention.

Clinical Ink piloted an mHealth sub-study with 30 subjects using a hybrid bring-your-own-device (BYOD)/provisioned device model, and results have indicated a low 6% subject dropout rate; a high average study procedure compliance of 84%; and high data quality. These data suggest that mHealth has an impact on reducing subject dropout rates, potentially improving protocol adherence and changing patient behaviour.

Research has shown that mHealth significantly enhances medication adherence, reduces non-adherence related adverse effects, and is accepted in healthcare in various geographic settings and among diverse demographic groups (1). Studies have also demonstrated that mHealth improves both recruitment and enrolment in clinical trials (2,3). Considering this with data showing nearly 43% of the global population and 68% of US adults owning a smartphone in 2015, advancing a BYOD approach (such as apps on a patientís smartphone) in mHealth is inevitable (4,5).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Kyle Hogan is eClinical Solutions Director with Clinical Ink, and is responsible for the strategic alignment of the companyís native mobile application for clinical trials. Kyle has delivered technical solutions for complex business challenges since the 1990s, and has more than nine years of experience in clinical trials.
spacer
Kyle Hogan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials

Reify Health today announced a $220 million Series C funding round led by Coatue Management, joined by ICONIQ Growth and Adams Street Partners, as well as existing investors Sierra Ventures and Battery Ventures.
More info >>

White Papers

What is process characterization?

EXPUTEC

Process characterization is an essential step in the commercialization of a new (biological) drug. For drug product commercialization, manufacturers must validate the drugís manufacturing process. This ensures that the manufacturing process delivers consistently a quality product and that the patient is not at risk.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement